Wave Life Sciences Studies Fourth Quarter and Full Yr 2021 Monetary Outcomes and Supplies Enterprise Replace

Wave Life Sciences USA, Inc.

Medical information from a number of novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD anticipated in 2022

GalNAc-AIMers restore therapeutically related ranges of AAT for lung safety and scale back liver-damaging aggregates in preclinical examine; IND enabling toxicology research anticipated to provoke in 3Q 2022

FY2021 year-end money whole of $150.6 million offering runway into 2Q 2023

Wave to host investor convention name and webcast at 8:30 a.m. ET at present

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines firm dedicated to delivering life-changing

Read More Read More